Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 12, 2023 09:15 ET | Source: SciSparc Ltd

SciSparc Engages Investment Bank to Identify Potential Strategic Transaction Opportunities

TEL AVIV, Israel, Sept. 12, 2023 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of...
September 07, 2023 09:15 ET | Source: SciSparc Ltd

SciSparc Announces Initiation of Randomized Phase IIb Clinical Trial of its Proprietary SCI-110 for Tourette Syndrome

Initiation of trial to take place at the Tel Aviv Sourasky Medical Center, the Israeli clinical trial site TEL AVIV, Israel, Sept. 07, 2023 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq:...
September 07, 2023 06:00 ET | Source: SciSparc Ltd

SciSparc Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Requirement

No Immediate Effect on Nasdaq Listing or Trading of the Company’s Ordinary Shares TEL AVIV, Israel, Sept. 07, 2023 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), a...
August 14, 2023 12:20 ET | Source: SciSparc Ltd

SciSparc Ltd. Closes $1.3 Million Underwritten Public Offering

TEL AVIV, Israel, Aug. 14, 2023 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“SciSparc” or the “Company”) today announced the closing of a firm commitment underwritten public offering with...
August 10, 2023 09:10 ET | Source: SciSparc Ltd

SciSparc Ltd. Announces Pricing of $1.3 Million Underwritten Public Offering

TEL AVIV, ISRAEL, Aug. 10, 2023 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“SciSparc” or the “Company”) today announced the pricing of a firm commitment underwritten public offering with...
August 09, 2023 16:40 ET | Source: SciSparc Ltd

SciSparc Ltd. Announces Proposed Underwritten Public Offering of Approximately $1.3 Million

TEL AVIV, Israel, Aug. 09, 2023 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“SciSparc” or the “Company”) today announced that it intends to offer its securities in a firm commitment...
August 01, 2023 09:00 ET | Source: SciSparc Ltd

SciSparc and Clearmind Collaboration Continues to Increase its Patent Portfolio in the Field of Movement Abnormalities in the U.S.

TEL AVIV, Israel, Aug. 01, 2023 (GLOBE NEWSWIRE) -- The new U.S. patent application is for the use of the psychedelic molecule 3-MMC and SciSparc's Palmitoylethanolamide to treat dyskinesia and...
July 14, 2023 07:55 ET | Source: SciSparc Ltd

SciSparc to Commence Its Clinical Trial with SCI-210 in Children with Autism Spectrum Disorder

“We hope the outcome of this trial will enable the Company to procced with commercialization process for SCI-210 in Israel" TEL AVIV, Israel, July 14, 2023 (GLOBE NEWSWIRE) -- SciSparc Ltd....
June 30, 2023 09:25 ET | Source: SciSparc Ltd

SciSparc Receives Approval to Conduct Phase IIb Clinical Trial for SCI-110 to Treat Tourette Syndrome in Germany

The Federal Institute for Drugs and Medical Devices in Germany granted the Company approval to use SCI-110 in a clinical trial at the Hannover Medical School TEL AVIV, Israel, June 30, 2023 ...
June 21, 2023 09:00 ET | Source: SciSparc Ltd

SciSparc Announces IRB Approval to Conduct its Phase IIb Trial in Tourette Syndrome

Company reaches another clinical trial milestone for treatment of Tourette’s with its novel SCI-110 therapy in the United States TEL AVIV, Israel, June 21, 2023 (GLOBE NEWSWIRE) -- SciSparc Ltd....